文献速递中医内科中药与中成药合理使用

金芪降糖片治疗2型糖尿病的系统评价与Meta分析

A systematic review and meta-analysis on the efficacy and safety of traditional Chinese patent medicine Jinqi Jiangtang Tablet in the treatment of type 2 diabetes.
PubMed 文献 · Complement Ther Med · 2019-04-30

结果显示联合治疗在提高有效率、改善血糖血脂及胰岛素抵抗方面优于对照,但证据存在局限需谨慎解读。

要点

  • 金芪降糖片联合常规治疗可提高T2DM治疗有效率(RR 1.34,95%CI 1.02–1.75)。
  • 联合治疗显著降低FBG、2hPG、HbA1c、FINS、PINS、HOMA-IR及LDL-C、TC、TG。
  • HDL-C、不良事件总发生率及低血糖发生率组间无统计学差异。

核心结论

  • 金芪降糖片联合常规治疗T2DM在调节糖脂代谢和改善胰岛素抵抗方面表现良好。
  • 因本系统评价存在局限性,结果应谨慎解读。

研究设计与样本

  • 系统评价与Meta分析,检索7个电子数据库自建库至2018年5月24日。
  • 纳入金芪降糖片联合常规治疗对比常规治疗 alone 或联合安慰剂的随机对照试验。

主要发现

  • 有效率比较支持金芪降糖片组(RR 1.34;95%CI [1.02, 1.75];p=0.04)。
  • FBG降低(MD -0.85;95%CI [-1.03, -0.68];p<0.00001),2hPG降低(MD -1.95;95%CI [-2.33, -1.56];p<0.00001)。
  • HbA1c降低(MD -0.76;95%CI [-1.03, -0.49];p<0.00001),FINS降低(MD -3.05;95%CI [-3.69, -2.42];p<0.00001)。
  • PINS降低(MD -10.22;95%CI [-13.93, -6.50];p<0.00001),HOMA-IR降低(MD -1.11;95%CI [-1.55, -0.68];p<0.00001)。
  • LDL-C降低(MD -0.37;95%CI [-0.63, -0.11];p=0.006),TC降低(MD -0.46;95%CI [-0.85, -0.08];p=0.02),TG降低(MD -0.34;95%CI [-0.47, -0.20];p<0.00001)。

关键数值与推荐

  • HDL-C、不良事件总发生率及低血糖发生率两组间无统计学差异。
  • 结局指标以风险比(RR)或均数差(MD)表示,依据I²值选用固定或随机效应模型。

临床怎么用

  • 在常规治疗基础上联用金芪降糖片可能有助于改善T2DM患者糖脂代谢及胰岛素抵抗。
  • 临床决策需结合患者个体情况及证据局限性综合评估。

局限性

  • 原文明确指出该系统评价存在局限性,结果应谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: At present, a large number of people in the world are suffering from type 2 diabetes (T2DM), so it is urgent to develop effective treatment measures of T2DM. In China, many clinical studies have shown that Jinqi Jiangtang Tablet (JQJTT), a traditional Chinese patent medicine (TCPM), has a good effect in the treatment of T2DM. This systematic review and meta-analysis is intended to assess the efficacy and safety of JQJTT plus conventional therapy in the treatment of T2DM. METHODS: Seven electronic databases were searched to include in eligible studies published from inception to May 24, 2018. Randomized controlled trials (RCTs) of JQJTT in combination with the conventional therapy versus conventional therapy alone or combined with placebo were included. The two reviewers independently conducted data extraction and quality assessment. For different variable types, the outcome measures were expressed as risk ratios (RRs) or mean differences (MDs). According to the value of I2, a fixed or random effect model was used for statistical analysis. RESULTS: Seventeen studies conducted in China were identified in this systematic review, which included 1,425 participants. The meta-analysis on the effective rate of the comparison groups showed a significant difference in favor of the JQJTT group (RR 1.34; 95%CI [1.02, 1.75]; p = 0.04). In addition, the results showed a statistically significant reduction in FBG (MD -0.85; 95%CI [-1.03, -0.68]; p < 0.00001), 2hPG (MD -1.95; 95%CI [-2.33, -1.56]; p < 0.00001), HbA1c (MD -0.76; 95%CI [-1.03, -0.49]; p < 0.00001), FINS (MD -3.05; 95%CI [-3.69, -2.42]; p < 0.00001), PINS (MD -10.22; 95%CI [-13.93, -6.50]; p < 0.00001), HOMA-IR (MD -1.11; 95%CI [-1.55, -0.68]; p < 0.00001), LDL-C (MD -0.37; 95%CI [-0.63, -0.11]; p = 0.006), TC (MD -0.46; 95%CI [-0.85, -0.08]; p = 0.02), TG (MD -0.34; 95%CI [-0.47, -0.20]; p < 0.00001) with JQJTT plus conventional therapy versus conventional therapy alone. There was no statistical difference between the two comparison groups in HDL-C, total incidence of adverse events and incidence of hypoglycemia. CONCLUSION: The available evidence indicates that JQJTT combined with conventional therapy for treating T2DM has a good performance in regulating glycolipid metabolism and improving insulin resistance. However, due to the limitations of this systematic review, the results should be interpreted with caution.

来源:Complement Ther Med,查看原文。版权归原作者所有。

引用

  1. Gao H, Yang Y, Deng J, et al. A systematic review and meta-analysis on the efficacy and safety of traditional Chinese patent medicine Jinqi Jiangtang Tablet in the treatment of type 2 diabetes. Complement Ther Med. 2019. PMID: 31780013. doi:10.1016/j.ctim.2019.01.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。